Compare Lumen Technologies Inc (LUMN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Lumen Technologies Inc trades at $6.44 (market cap $6.47B), while State Street SPDR S&P Biotech ETF trades at $151.72. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals.
| LUMN | XBI | |
|---|---|---|
Market Cap | $6.47B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $11.83 | $164.28 |
52-Week Low | $3.70 | $85.16 |
Enterprise Value | $18.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $6.275, down 0.08% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of $1.74B in 2025 despite beating EPS estimates in two of the last three quarters. Recent news highlights strategic acquisitions like Alkira to bolster its AI networking capabilities, while the balance sheet shows high debt levels of $17.49B long-term.
The outlook remains challenging due to persistent losses and heavy debt, though cost-cutting initiatives and a $13B contract backlog offer potential upside. Analyst consensus is cautious with a $8.25 price target, but the stock's deep value (P/S 0.52) may attract contrarians if EBITDA improves. Key risks include execution on turnaround plans and interest expense pressure.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
